Corcept Therapeutics (CORT) Net Equity Issued and Repurchased (2011 - 2023)

Corcept Therapeutics (CORT) has 12 years of Net Equity Issued and Repurchased data on file, last reported at $1.8 million in Q4 2023.

• For the quarter ending Q4 2023, Net Equity Issued and Repurchased rose 124.33% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2023 stood at $5.8 million (up 32.64% YoY), and the FY2023 full-year result was $5.8 million, up 32.64% from the prior year.
• Net Equity Issued and Repurchased grew to $1.8 million in Q4 2023, from $1.1 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $10.0 million in Q4 2020 to a low of $480000.0 in Q1 2020.
• A 5-year average of $2.9 million and a median of $1.8 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased jumped 741.25% in 2021 and plunged 88.42% in 2022, its largest moves.
• Tracing CORT's Net Equity Issued and Repurchased over 5 years: stood at $1.8 million in 2019, then surged by 462.27% to $10.0 million in 2020, then sank by 69.49% to $3.0 million in 2021, then slumped by 74.24% to $785000.0 in 2022, then soared by 124.33% to $1.8 million in 2023.
• Business Quant data shows CORT's Net Equity Issued and Repurchased at $1.8 million in Q4 2023, $1.1 million in Q3 2023, and $1.5 million in Q2 2023.